ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025)

ENDRA Life Sciences (NDRA) reported Current Deferred Revenue of $328610.0 for Q2 2025, down 15.9% quarter-over-quarter from $390722.0 in Q1 2025.

ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025) Analysis & Trends

ENDRA Life Sciences (NDRA) has 2 years of Current Deferred Revenue data on file, last reported at $328610.0 in Q2 2025.

Current Deferred Revenue for Q2 2025 came in at $328610.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $328610.0 (changed N/A YoY), and the FY2024 annual result was $799284.0, changed N/A from the prior year.
Current Deferred Revenue slipped to $328610.0 in Q2 2025 per NDRA's latest filing, from $390722.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $910556.0 in Q3 2024 and troughed at $328610.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	30,529.42 Bn	30,528.96 Bn	1.11 Bn
2	Thermo Fisher Scientific	183.75 Bn	180.50 Bn	7.74 Bn
3	Danaher	133.13 Bn	127.43 Bn	3.59 Bn
4	Idexx Laboratories	46.14 Bn	45.94 Bn	722.74 Mn
5	Agilent Technologies	38.20 Bn	36.39 Bn	990.00 Mn
6	Natera	31.50 Bn	30.40 Bn	696.04 Mn
7	Iqvia Holdings	31.34 Bn	29.36 Bn	1.36 Bn
8	Illumina	24.51 Bn	23.36 Bn	721.00 Mn
9	Mettler Toledo International	23.53 Bn	23.47 Bn	555.82 Mn
10	ENDRA Life Sciences	5.24 Mn	4.89 Mn	-

Download Data